La chaîne d'options affiche les données clés des options sur actions de ESS Tech à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour ESS Tech..

ESS Tech (NYSE:GWH) Stock, Chaîne d'Options

ESS Tech

ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.

ESS Tech Inc

Global Wholehealth Partners Corp

Mizuho analyst Maheep Mandloi maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Outperform and lowers the price target from $16 to $13.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Sunrun, Lowers Price Target to $13

<a href="https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai" title="https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai">https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai</a>

BABA

'How Alibaba Helped China Take the Lead From the U.S. in Open-Source AI' - The Information

Contracts

CETX

Cemtrex's Vicon Receives $0.8M Contracts From U.K. Correctional Facilities

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled "<a href="https://www.globenewswire.com/Tracker?data=B-RN4N7zHYvKUcdnjlk4jtgfVTPS2vdvJO8iwTfiBBQKgcGy73ar6qKxYKUSQGCyhZlU8iU25vJPDpq-Py27VtL8RMaAeAYYH8VDAoQflHL4J3VgRcOg3S3xvZuFl_zErpFmLBusrqy1dx8nVX7TT26x5aRVrFfN3s48dpx1OHoJvAKl6ec0x76h0rkWNwg1ACmHbWI3Rei8CuA4sof5mWssyBPzpfRSLwkvjI2YsOzPjG7KCdv2nEzTG64q_qRbp6dw9BQA2KOU7R0B2et_Mv32ywfx5dyEHK3CzMVpbRxeeO15huBs6bT7oLzU3piEkCqWeOINLkOq956W9SisJUwSrWtTWRwmTyETP7w185JpH0Nkl4zV1l76j62-WrmuRp1bEuHANGZtJPKblL_GURjd2rdCPGhqW4HxQ-I0bS-Hj6jzqt1akX3PXcckl42Km8-RghXycIO7tACZHaEbWGubp2h2wxvkDS7cr0LFcIXcIQOXKQUgYnre5osm0liUtN7CYOkL3q3lAOlJ5gV6ktumZ_7ZRVBP3ghWQ02OJ83xfX2ybud5XrLg7Chpe6bauNL76O0UmAqm4AetGCX98xMcmVIDc1QI10GCwCq80KJz3TPSm0bwNVimcvG0HcQGXddY1Vd6CzichWAPGs3WkEKwJY5pKFFQmg_1CMjQVaXAWc_VbUV7LEzasTQD44b-12jfW37MIlcnQm8VeXyXTo-vTsQxWj0jIWmFGQopKPwHB5FS4Y75kLeAhnBxhD9Du8AAlpfsbzes2iNbPqHuo15jHsd2wrS48QajBft3aDXKmdKyPYTsRfoZcMAjcfpYDZX5h2TsHaOJ7AfKcywPtahZaFYTTbKq3fmHvoVUZuvTBxLE-dQVXtOoupqQtQMpQ3-GAtRErvTO0pNQUKAt-1s-JcHUIfjMww815oeTB_9tpiOQ4SZK-VSfG4wx72Id6J5Mp0z0VwkYtcaL0TqVKETDao4ezhfrV4vqpZ4wSAVDVIL5hBAkNDLZsbbq10iV6EZRSltD0gWTQW-mHeDCXshBp8oce7BkAGtoPpYyesoDAoOwofiVeBFIrcwx_rz3wB3UWN4-C09cD4WtObDHYkKzecAXO9ZWnJN2aCCjRTzq3GVTUrY51fUyYpgXKxILjgsdOJxgaTVFAucXh435z-d3mxAzNvNUkxKeBWhpVy3wa_YF0Jgb5LyOb7mmPRv-fRnPuOZbpZTxvaSTnNucMSHKV1m0WCwJJb_8Y4QYMBClpw_vK25nbysSVICSUTtv73_cNxBzUpA6SUsnGV-VyYs55xZF3SuqQgO4849OgHJm1utK1f_q6RuPRx6_-l8vzWPDhkmArnkee6iLlzbRJPzfFEj7Nev9vGZbBRmv6iwwkRihobf85fwS1DpwzUa_5S97iZHM7d2377H9nCe3OCBAYhgm-qtut3cB4FGw7r4gzHDEbOYPiWSh2zEj92h1Y8jxKY73PopD1aqcvUxEEkNvXuXG2JxC3E_IDY6yJCs61DAgDcU0EcXdgQlsApTP4s9nIQ74zhE4yCJxxmV7xURXVjC8V75mvN60Gf_uXW4qCLhgqNbJNq5LI3fi20Y7jzBKScqNscKx7WqENT6qU8xzo3EAVpuiHbYUQf_aqjC5TytUmazd7338gB_iOy1qVXxXc5EJLXbFjQ2zO443ypPIsFpQGLy2gsMnGzVyUiJ5UIcP2F04BMjaU2uwn9wKyX_BI50sdQNvOwW5rtLRKQw-CCCxYDZCSCRMZGikoGiVs9ahpLrRVYV6MrIe_It9Iy8yWQnASweTB8LKKljy0kdJY08jEUyp768owoVyBj_3JYabbE21Qb6ANI_Cf7ZKZPqNpf1rjCvsuErctjj3UYXVyFvYFBOZHEDq7r4dcmgmc8Jp36KPwAjQw9Dj1tI2HYxWQbvxAtipMoPwLnAMKRob7JwQfdnrwYjLLVbtG_j_CRQ4AgfHj2YQUgmoQDh1EYKeq0ceogsacnxmsPUM9X0VSpFzuRkW2EjA7FEXxxvfkEdGpGAoxlRYejYmU8ctJs__2r_sTlx1pMzaWpa-xYNEhjS5wy6mFe22lgCBKx6UdecX_FwaE3ohf9U9RgXk7eaI2jhmPlQiXNUeNTfM_Tq8hp5y1KlF64sPwg0N6m-8oYIRIjKx3vTr5ulOhlefIcKI6C525fTw8etoHJQs5wd7I9apqcw1RkUqHns_j85Jxvx2Nl3-CQoqLmmfiDqV22UiwjSDNF5rckmM4eayMElC4dmUoTTMQ3k56Q-hIb2Qa9vXQoRpSowCSs0SMLn5GM3_RJUDl_aixjxD2YQjavah63li0pVrRzrY1rDrONeVL8eVoQMcQplvUhTpWF-SwVBwJ9BoeAwSCxV0YdJa6x-SzXKQHGXwKMMdU5b4KmX1rAvFlog5MaEmKUQOrZkA5uQt30UenpGnd5kdbJYj3w0M7xHesA-k6_1pWottxahsRm9NwT1JC8kBKt_t2Zorkd2SdycTxQIdNDHu2tTddktCiS0vCtlFrA8LvVi6s3Pd1_kOKdp6Xkf9LkxoFroY9WHxa0sVbmcDkKtfVOzjlIq78skeN0tx_mIJyYrsr6g1oOFRjc7tHgj42nmK25w5qem2orvWwv83boISDW1CmRRh6-A06f_5g4sGIn1Zz3tWKbuI9O1l3FRre4HoQCn_miaFoNKbmLCh-_1bmfrH30ClrIyby7xe6uW65cfcON1XA-7mnvtPAwSuSySbKsa0h0DW6PXkF3V0AaJUYflTQ9YWERjMAH9qMVODCUDOW3CCJB0xRgzmbqKvTuuHp00su6JUkTKCst39-HAvJpuKsAleAkvlwZZ7-Fs0s1IMH4Ufu433dKoXQWCJhOQx2-06aa5ogdCt-f8rYA8JU_NZ3Km5TKJTEIACMzkhew4OR_3IgskJd-v7LsRpCK5X9CftLsRmrluOfS3XObAIgI5NIYd4kvuWw-CrVeWApCbUD4rpoGpqgyO1Z-XvdgLAXFjjLwsKktuokSUUSEM0TwqrvdKGmxdtlq4yl8OP78pERag=">Fatty acid binding proteins and their involvement in anxiety and mood disorders</a>," that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders.
The peer-reviewed article was co-authored by Doctor Steven Laviolette, Professor in the Schulich School of Medicine along with other researchers from the University of Western Ontario, Canada, details extensive preclinical evidence supporting FABP5, FABP3, and FABP7 as key regulators of lipid trafficking, neuroinflammatory signaling, and endocannabinoid tone — mechanisms critically involved in the pathophysiology of anxiety and depression.

Biotech

General

ARTL

Artelo Biosciences Welcomes Publication Of Peer-Reviewed Review Highlighting Therapeutic Potential Of Fatty Acid Binding Protein Inhibitors In Treating Anxiety And Mood Disorders, Underscoring Key Roles Of FABP5, FABP3, And FABP7 In Neuroinflammation And Endocannabinoid Regulation

Mizuho analyst Maheep Mandloi maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Neutral and raises the price target from $15 to $18.

SEDG

Mizuho Maintains Neutral on SolarEdge Technologies, Raises Price Target to $18

<a href="https://www.globenewswire.com/Tracker?data=t6BzLIYkM2Titjo2engsbYdYzVAKdATUpngXwVnOZLIFJeWOfs8JrzmA569pg5PP_wzcfVu2vxAkFgwTviT40sMP1XwBJn9-iup44hY2Ll8=">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise&#x2122; MRD Test to detect and monitor ctDNA in patients.
The interim results – first shared at the <a href="https://www.globenewswire.com/Tracker?data=BdItqSDA6Al6o-I38SIC8HVerhVbF4nmX3ccqI_QUByE92yXbvem_fZDt7OQiI8cB2NKQK4abOO6M6jL-D0tMte8h9L5gZyDFjQTEqQDUNNJPBB4ksABOeMgezfAqA3z09nF2QurM9LI5SGkqo5aWA==">2025 ASCO Annual Meeting</a> by Tadayoshi Hashimoto, MD, PhD of the NCCHE – achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess because of low levels of ctDNA in blood. Key findings include:
<ul>
<li>Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested.</li>
<li>Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.</li>
<li>Clearance of ctDNA during neoadjuvant chemotherapy, as shown by Precise MRD, predicted pathological complete response. &nbsp;</li>
</ul>
"Previous studies have shown that ctDNA-based MRD detection significantly correlates with recurrence risk and predicts benefit of adjuvant chemotherapy in certain cancers," said Takayuki Yoshino, MD, PhD of the NCCHE and principal investigator for the MONSTAR-SCREEN-3 study. "However, first-generation MRD assays appear to have limited sensitivity in low ctDNA-shedding tumors. For our pan-cancer study, we selected Precise MRD because of its enhanced sensitivity across diverse tumor types."
"Our results showed that among samples that were ctDNA-positive at the one-month post-surgery timepoint, 60% had ctDNA levels in the ultra-sensitive range that may not have been reported as positive by first generation MRD tests," said Dr. Hashimoto. "In addition, these patients had significantly worse disease-free survival compared to those that were ctDNA-negative, demonstrating the importance of ultra-sensitive ctDNA detection."
"The initial results from the study highlight the tremendous potential for utilizing Precise MRD across cancer types to enhance personalized treatment and therapeutic strategies for patients," said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. "Precise MRD is informed by WGS, enabling the tracking of thousands of tumor-specific sites, far more than what is possible with first-generation MRD tests. Tracking so many variants yields exceptional sensitivity even in cancers with low shedding tumors such as breast and renal. A key benefit of our ultrasensitive assay is confidence in ctDNA results, as shown by the finding that the ctDNA status after neoadjuvant treatment was strongly associated with pathological response."

MYGN

Myriad Genetics Announces MONSTAR-SCREEN 3 Data, Advancing Pan-Cancer MRD Testing

<ul>
<li>Authorized expanded access for ANKTIVA to treat lymphopenia, a life-threatening immune deficiency induced by chemotherapy, radiotherapy, and immunotherapy with depletion of natural killer (NK) and CD4+ CD8+ T cells (lymphocytes)</li>
<li>Expanded Access includes all patients with solid tumors who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC &lt;1,000/μL)
<ul>
<li>Presentation at ASCO Annual Meeting 2025 of lymphopenia treatment in patients with 3rd to 6th line metastatic pancreatic cancer significantly prolongs overall survival</li>
</ul>
</li>
</ul>

IBRX

ImmunityBio Receives FDA Expanded Access Authorization For Treatment Of Lymphopenia With ANKTIVA In Patients With Solid Tumors

Board Initiates CEO Search Process
Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed
Company Reaffirms Full Year 2025 Outlook
LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors.
The Nature's Sunshine Board has initiated a comprehensive search process, with the assistance of a nationally recognized executive search firm, to identify the Company's next President and Chief Executive Officer.

Guidance

Management

NATR

Nature's Sunshine Products Announces CEO Terrence Moorehead To Step Down Upon Successor Appointment, Board Launches Executive Search Process While Reaffirming Full Year 2025 Outlook

Stock Split

CLRO

ClearOne Authorizes 1-fFr-15 Reverse Stock Split

- Expert Insights on Clinical Relevance and Scientific Rationale - The replay of the event is available on the Investor Relations section of the Actuate website
CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced key takeaways from its <a href="https://www.globenewswire.com/Tracker?data=ny_7s0D-DqkX-BPpPbP_wQtFovQZxuvRSw4gk6tVSoZGjR14bMEO2op3qnVein761Xie2vWUKkbXa0LDrdeZEVTJl4Aw6C1DeRqFFuuqeg1BPOdvquOX2UW3UpV2FF0pjjU7STsQjumtaJ5ZutZM1w==">Key Opinion Leader (KOL) event</a> held on May 31, 2025 discussing the positive topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
The study met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival (mOS) of 10.1 months compared to 7.2 months (p = 0.01), with a 37% reduction in the risk of death (HR = 0.63). The elraglusib/GnP arm also doubled the 12-month survival rate in 44.1% of patients compared to GnP alone (22.3%), with a favorable safety profile.
The KOL event followed the presentation of topline trial data during an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting. The event featured a fireside discussion with leading mPDAC clinicians, all with direct participation in the elraglusib clinical trial program: Colin Weekes, MD, PhD, Massachusetts General Hospital; Devalingam Mahalingam, MD, Northwestern University Feinberg School of Medicine; Rachna Shroff, MD, MS, FASCO, University of Arizona Cancer Center; Tanios Bekaii-Saab, MD, FACP, Mayo Clinic College of Medicine and Science.
The panelists highlighted the implications of the Phase 2 Actuate 1801 Part 3B results in the broader context of the unmet need in mPDAC, the unique immune-modulating mechanism of elraglusib, and its potential to reshape the treatment landscape, as follows.

ACTU

Actuate Therapeutics Highlights Insights On Phase 2 Trial Results Showing Clinically Meaningful Survival Benefit And Favorable Safety Of Elraglusib Combined With Gemcitabine/Nab-Paclitaxel In Untreated Metastatic Pancreatic Cancer At KOL Event

Mizuho analyst Maheep Mandloi maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Outperform and raises the price target from $6 to $7.

SHLS

Mizuho Maintains Outperform on Shoals Technologies Gr, Raises Price Target to $7

The new task order is the first to be fulfilled under the $450 million Production-Other Transaction Agreement recently awarded to C3 AI.

C3 AI Wins $13M Order To Expand Predictive Maintenance Program Across U.S. Air Force Fleet

Palladyne AI included in annual reconstitution of the Russell U.S. Indexes capturing 4,000 largest U.S. stocks for 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.palladyneai.com%2F&amp;esheet=54262364&amp;newsitemid=20250602973600&amp;lan=en-US&amp;anchor=Palladyne+AI+Corp&amp;index=1&amp;md5=e4e79a7c27f7d29dbdcb80a7a8a87be9">Palladyne AI Corp</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) ("Palladyne AI"), a developer of artificial intelligence software for robotic platforms in the defense and commercial sectors, today announced that it has been added as a member of the broad-market Russell 3000&#xAE; Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution.
The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000&#xAE; Index or small-cap Russell 2000&#xAE; Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

PDYN

Palladyne AI Corp. To Join Russell 3000 And Russell 2000 Index, Effective After The U.S. Market Opens On June 30, 2025

TD SYNNEX Appoints Kenneth Lamneck As Chair Of Nominating And Corporate Governance Committee

Mizuho analyst Anthony Crowdell maintains Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Outperform and raises the price target from $60 to $67.

Mizuho Maintains Outperform on Nextracker, Raises Price Target to $67

<a href="https://www.globenewswire.com/Tracker?data=xdSkUqkMsHzXmkeMPxPhQH6bn-h7JG8NEb30yHWLcWTBly9NJDanE39FJd_1jbdbRapwl3IF95i3r9C7aa--NBjeMyDEyh-fc2nyq5_UNsA=">Aeries Technology, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>), a leading provider of Global Capability Center (GCC) solutions, today announced a strategic partnership with <a href="https://www.globenewswire.com/Tracker?data=v2IS8QBS8duxDdUdtMPBv8MUCf9n3E8pr6zSZWCeqzd7KyH7IrpofI6kTOSlzbucLbNdXHhnIRRI3qRmcrzc3w==">Fortra</a>, a global cybersecurity software and services provider. This collaboration is aimed at establishing GCCs for Fortra in both India and Mexico, to expand their existing India-based workforce and add a nearshore hub.
Aeries will leverage its expertise to deliver purpose-built solutions through these GCCs, focusing on enhancing core business functions. The GCCs will enable Fortra to further access a skilled and diverse talent pool, ensure cost efficiency, and scale operations, aligning strategically with their business objectives. These facilities will serve as a hub for fostering innovation, optimizing operational efficiency, and accelerating digital transformation initiatives.

Advanced Environmental Recycling Technologies

AERT

Aeries Technology Announces Strategic Partnership With Fortra To Expand Existing India-Based Workforce And Add Nearshore Hub

Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN <a href="https://www.benzinga.com/general/health-care">Phase 3 trial data</a>.
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44720573/kidney-disease-focused-vera-therapeutics-concludes-enrollment-in-pivotal-study-targets-2026-commercial-launch" rel="noreferrer noopener">Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch</a>
For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717296/vera-therapeutics-announces-atacicept-achieved-46-proteinuria-reduction-in-origin-phase-3-trial-in" rel="noreferrer noopener">ORIGIN Phase 2b trial</a>.
The safety profile of atacicept in this analysis was favorable and comparable to that of the placebo.
Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.
Vera is poised for potential commercial launch of atacicept in 2026, according to Marshall Fordyce, CEO of Vera Therapeutics.
Vera is currently not sharing estimated Glomerular Filtration Rate (eGFR) results.
The trial continues in a placebo-controlled, blinded manner to evaluate the change in kidney function over two years as measured by eGFR and is expected to be completed in 2027.
Price Action: VERA stock is up 58.9% at $30.33 during the premarket session at the last check on Monday.
You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Vera Therapeutics, which is trading at $18.95 as of publishing time, $100 would buy you 5.28 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> 
If your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/05/45703150/gap-flags-over-100-million-tariff-burden-outside-guidance-near-term-stock-pressure-likely-analyst" target="_blank" rel="noreferrer noopener">GAP Flags Over $100 Million Tariff Burden Outside Guidance, Near-Term Stock Pressure Likely: Analyst</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

Trading Ideas

VERA

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Oscar Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) short percent of float has risen 15.08% since its last report. The company recently reported that it has 19.07 million shares sold short, which is 9.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Oscar Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748869272_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Oscar Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Oscar Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Oscar Health's peer group average for short interest as a percentage of float is 2.31%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

OSCR

How Do Investors Really Feel About Oscar Health?

Interparfums's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NYSE">IPAR</a>) short percent of float has fallen 6.09% since its last report. The company recently reported that it has 1.09 million shares sold short, which is 6.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Interparfums Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748869267_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Interparfums has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Interparfums's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Interparfums's peer group average for short interest as a percentage of float is 5.77%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

IPAR

How Is The Market Feeling About Interparfums?

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.6, a high estimate of $84.00, and a low estimate of $61.00. A decline of 6.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748869261_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$64.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Centene. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Centene's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Centene analyst ratings.</a>
<h2>Discovering Centene: A Closer Look</h2>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 15.38%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Centene's debt-to-equity ratio is below the industry average at 0.66, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Centene: 5 Analysts Share Their Views

Press Releases

ESS Tech, Inc. Announces Third Quarter 2024 Financial Results

ESS Celebrates Commercial Launch of Energy Center™ Product

ESS Announces Actions to Position the Company for the Future

ESS Global Fleet Achieves Operational Milestone Surpassing 2 GWh of Transacted Energy

ESS Schedules Fourth Quarter and Full Year 2024 Financial Results Conference Call

ESS Tech, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

ESS Recognized as TIME Top GreenTech Company and one of Fortune's Most Innovative Companies in America for 2025

ESS Schedules First Quarter 2025 Financial Results Conference Call

ESS Tech, Inc. Announces First Quarter 2025 Financial Results

ESS Confirms Path to Continued Execution of its Strategic Plan with the Energy Base

Advent Technologies Holdings, Inc. - Class A Common Stock

Advent Technologies Hldgs

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

ESS Tech

ESS Tech (GWH) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL